Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 12/20 | 0.70 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MYC | P01106 | 2/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | UHRF1 | Q96T88 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239943 | 0.90 | MYC (0.79) | APEX1USP2POLBKDM4EMEN1 | |
| SCHEMBL18293210 | 0.90 | MYC (0.79) | APEX1USP2POLBKDM4EMEN1 | |
| SCHEMBL18293195 | 0.90 | MYC (0.79) | APEX1USP2POLBKDM4EMEN1 | |
| SCHEMBL18285729 | 0.86 | APEX1 (0.56) | APEX1USP2POLBKDM4EMEN1 | |
| SCHEMBL18293180 | 0.85 | APEX1 (0.71) | APEX1USP2POLBKDM4EMEN1 | |
| SCHEMBL13734396 | 0.83 | APEX1 (1.00) | APEX1USP2POLBKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL14777718 | 0.82 | APEX1 (0.98) | APEX1USP2POLBKDM4EMEN1 | |
| SCHEMBL18285859 | 0.82 | APEX1 (0.51) | APEX1USP2POLBKDM4EMEN1 | |
| SCHEMBL1494905 | 0.80 | APEX1 (1.00) | APEX1USP2POLBKDM4EMEN1 | |
| SCHEMBL20248809 | 0.80 | APEX1 (0.58) | APEX1USP2POLBKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-10787444-B2 | Compounds for the modulation of myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10787444-B2 | Compounds for the modulation of myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| WO-2016197078-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016197078-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | APEX1 1196/4885USP2 4320/4885POLB 1894/4885 |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | APEX1 1879/4885USP2 4506/4885POLB 1221/4885 |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | APEX1 1879/4885USP2 4506/4885POLB 1221/4885 |
| US-10787444-B2 | Compounds for the modulation of myc activity | MYC, MYCBP, MYCBP2 | APEX1 1196/4885USP2 4320/4885POLB 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.